Novartis BP drug sees approval in Europe
The approval follows an FDA endorsement earlier this year in
Analysts have estimated peak sales of between $2.5 billion to $3.5 billion for the Novartis pill, which was co-developed by Swiss biotech company Speedel.
When used alone, Rasilez demonstrates greater blood pressure lowering than other commonly-used blood pressure medicines, like ACE inhibitors and certain diuretics. When added to existing therapy, it provides additional blood pressure lowering, the company said in a statement.
Novartis said nearly a billion people around the world have high blood pressure, and almost 70% do not reach their blood pressure goal.
Tekturna targets renin, an enzyme responsible for triggering a process that can contribute to the condition.